Saturday 17 October 2026
Export CNMD’s income statement to Excel — free account
CONMED Corporation
CNMD Healthcare Medical Devices
CONMED Corporation’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 5.18% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 11.6%, free cash flow grew 46.0% and total debt fell 5.40%, each against the same quarter a year earlier. Dividend growth for ten consecutive years, revenue growth for five, operating cash flow growth for three.
46.72
0.42
−0.89%
Follow CNMD
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 5.53% | 5.50% | 4.72% | 6.60% |
+8 more TTM periods Free account |
|
Piotroski F-Score |
6 | 6 | 5 | 5 | |
| 2.44% | 2.38% | 2.03% | 2.76% | ||
ROIC |
3.75% | 3.80% | 3.51% | 4.06% | |
Return on Tangible Assets |
17.10% | 11.20% | 9.99% | 13.94% | |
Average Days of Receivables |
63.80 | 60.90 | 65.80 | 60.93 | |
Free Cash Flow per Share |
4.47 | 4.04 | 4.86 | 4.81 | |
Free Cash Flow |
134.46 | 123.71 | 150.88 | 148.96 | |
Capital Expenditures |
(16.12) | (18.92) | (19.81) | (18.73) | |
| Other line items | |||||
Cash ROIC |
7.03% | 6.46% | 7.90% | 7.84% | |
Accounts Receivable Turnover |
5.79 | 6.09 | 5.66 | 5.91 | |
Accounts Payable Turnover |
6.00 | 6.11 | 6.37 | 5.83 | |
Inventory Turnover |
1.68 | 1.70 | 1.78 | 1.75 | |
Average Days of Payables |
60.81 | 62.63 | 54.76 | 63.36 | |
Days of Inventory on Hand |
216.81 | 217.51 | 207.89 | 215.56 | |
Tax Rate |
(0.32) | (0.33) | (0.34) | (0.25) | |
Research and Development Expense of Revenue |
4.42% | 4.32% | 4.07% | 4.02% | |
Selling, General and Administrative Expense of Revenue |
43.33% | 42.67% | 43.06% | 41.40% | |
Share Based Compensation of Revenue |
1.48% | 1.46% | 2.06% | 2.19% | |
Interest Coverage |
3.69 | 3.75 | 3.30 | 3.64 | |
Operating CF/Net income |
2.67 | 2.60 | 3.63 | 2.62 | |
Depreciation/Fixed assets |
0.73 | 0.72 | 0.71 | 0.71 | |
Capex/Depreciation |
(0.20) | (0.24) | (0.25) | (0.24) | |
Revenue per Share |
45.62 | 44.81 | 44.29 | 43.53 | |
Operating CF per Share |
5.01 | 4.66 | 5.50 | 5.42 | |
Capex per Share |
(0.54) | (0.62) | (0.64) | (0.61) | |
Capex to Sales |
0.01 | 0.01 | 0.01 | 0.01 |
Columns are period end dates